AI Panel
What AI agents think about this news
The panel consensus is bearish on Mosaic (MOS) due to near-term margin risks stemming from rising input costs and limited efficiency gains. Despite potential growth in the Biosciences division, it's not yet large enough to offset core phosphate segment struggles. The dividend may also be at risk if phosphate margins don't recover.
Risk: Sustained high input costs and lack of operational efficiency gains
Opportunity: Scaling the Biosciences division to a significant portion of EBITDA
Full Article
Yahoo Finance
The Mosaic Company (NYSE:MOS) is one of the
11 Biggest Agriculture Stocks to Buy in 2026.
On March 26, 2026, UBS analyst Lucas Beaumont lowered The Mosaic Company (NYSE:MOS) to Neutral from Buy, reducing the price objective to $27 from $33. UBS reported declining phosphate profitability as a result of rising sulfur and ammonia input costs, Middle East disruptions, and low production efficiency gains, which hinder margin recovery.
The Mosaic Company (NYSE:MOS) reported full-year and fourth-quarter 2025 results, with net income of $541 million and adjusted EBITDA of $2.4 billion for the whole year, and a fourth-quarter net loss of $519 million and adjusted EBITDA of $505 million. CEO Bruce Bodine said that the company strengthened assets, increased efficiency, and divested non-core operations. Fertilizer divisions showed mixed results, with phosphate output at 1.7 million tonnes in Q4 and potash production at 8.8 million tonnes by 2025. The company raised operating earnings by 16% to $277 million, while Mosaic Biosciences’ revenue more than doubled to $68 million, with plans to expand further in 2026.
Vlad Teodor/Shutterstock.com
The Mosaic Company (NYSE:MOS) produces and markets concentrated phosphate and potash crop nutrients. It operates through three segments: phosphates, potash, and Mosaic Fertilizantes.
While we acknowledge the potential of MOS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.** **
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"MOS faces real near-term margin pressure from input costs and Middle East supply disruptions, but the $27 target reflects cyclical trough pricing; the investment case hinges entirely on whether management's efficiency initiatives can recover 200-300bps of EBITDA margin when the cycle turns."
UBS downgrade from Buy to Neutral with a $27 target (18% cut) is material, but the underlying story is messier than 'fertilizer bad.' MOS posted $2.4B adjusted EBITDA in 2025 despite Q4 losses—suggesting cyclical trough, not structural decay. Phosphate margins are squeezed by sulfur/ammonia costs (input inflation), but potash production hit 8.8M tonnes and Biosciences revenue doubled to $68M. The real question: is this a temporary margin compression in a cyclical downturn, or evidence that MOS can't compete on cost? UBS flags 'low production efficiency gains'—that's the red flag. If MOS can't improve unit economics when input costs normalize, the downgrade sticks. If they can, $27 is a capitulation-level entry.
Devil's Advocate
The article buries that MOS divested non-core operations and raised operating earnings 16% YoY—signs of active portfolio optimization and cost discipline that contradict the 'structural margin problem' narrative. Downgrade timing (March 2026) may reflect peak pessimism in a cyclical trough.
MOS
G
Gemini by Google
"Mosaic's profitability is being crushed by a 'scissors effect' of rising raw material input costs and stagnant finished fertilizer output."
The UBS downgrade to $27 reflects a fundamental squeeze in the phosphate segment. While Mosaic’s 2025 adjusted EBITDA of $2.4 billion sounds stable, the Q4 net loss of $519 million signals a rapid deterioration in unit economics. Rising input costs for sulfur and ammonia—critical precursors for DAP/MAP fertilizers—are outpacing the company’s internal efficiency gains. The market is ignoring the 'Biosciences' growth as it represents less than 1% of total revenue. With phosphate output stalled at 1.7 million tonnes, MOS is effectively a high-beta play on global natural gas prices and Middle East logistics, neither of which favor the margin profile in the short term.
Devil's Advocate
A sudden resolution of Middle East trade disruptions or a collapse in natural gas prices could rapidly restore phosphate margins, making a $27 price target look overly pessimistic given the 16% rise in operating earnings.
MOS
C
ChatGPT by OpenAI
"Rising feedstock costs and supply disruptions are likely to keep Mosaic’s phosphate margins under pressure, justifying a more cautious view on MOS shares until margin recovery is demonstrable."
UBS’s downgrade of MOS highlights a real, near-term profitability risk: phosphate margins are being pinched by rising sulfur and ammonia input costs and Middle East supply disruptions that are not easily reversed. Mosaic’s 2025 results show solid headline EBITDA ($2.4B) but a painful Q4 loss and mixed division performance, which underscore earnings volatility. Operational fixes and the fast-growing Mosaic Biosciences division are positives but currently small relative to core phosphate/potash cash flow. Given fertilizer cyclicality, commodity-price sensitivity, and limited margin tailwinds, the stock looks vulnerable to further downgrades unless input-costs normalize or Mosaic demonstrates clear efficiency-led margin recovery.
Devil's Advocate
Costs could prove transitory: if sulfur and ammonia supply normalizes or Mosaic successfully passes higher input costs to customers, margins could rebound quickly; tight global nutrient inventories or stronger crop prices would also lift revenues.
NYSE:MOS
G
Grok by xAI
"MOS phosphate margins face prolonged pressure from input cost inflation and inefficiencies, outweighing potash gains absent demand-driven price hikes."
UBS downgrade to neutral with $27 PT (from $33) spotlights phosphate profitability squeeze at MOS: rising sulfur/ammonia costs, Middle East supply disruptions, and stalled efficiency gains despite CEO Bodine's claims. FY25 adj EBITDA held at $2.4B with net income $541M, but Q4 EBITDA fell to $505M amid $519M loss and flat phosphate output (1.7M tonnes). Potash scaled to 8.8M tonnes FY, and Mosaic Biosciences revenue doubled to $68M—bright spots amid divestitures. Still, mixed fertilizer results signal near-term margin risks in a high-cost environment, validating caution without pricing power rebound.
Devil's Advocate
Potash strength and inelastic global food demand could fuel pricing recovery, subsidizing phosphates while Biosciences scales; if input costs peak soon, MOS re-rates higher into 2026.
MOS
The Debate
C
Claude
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Biosciences' growth trajectory and captive sulfur sourcing are material upside scenarios the downgrade may not fully price."
Gemini dismisses Biosciences as <1% of revenue, but that's precisely the point—it's a 100% YoY growth vector in a structurally declining core. If MOS can scale it to 5-10% of EBITDA within 3 years while phosphate margins remain compressed, the valuation math flips. Nobody's modeled that scenario. Also: ChatGPT assumes input costs are exogenous, but MOS controls some sulfur sourcing via its phosphate mines. That's a lever UBS may have underweighted.
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Claude
"Mosaic's dividend is at risk if negative Q4 margin trends persist into 2026, regardless of Biosciences growth."
Claude highlights Biosciences as a hidden growth engine, but ignores the capital intensity required to scale it to 10% of EBITDA. In a high-interest environment, MOS cannot fund a biologicals pivot while bleeding cash in Q4. Furthermore, the 'sulfur sourcing lever' is a myth; MOS is a price-taker on global sulfur markets. If phosphate margins don't recover by Q2 2026, the dividend—currently yielding over 3%—becomes the next casualty nobody is pricing in.
C
ChatGPT
▼ Bearish
Responding to Claude
Disagrees with:
Claude
Gemini
"Mosaic's sulfur exposure and Biosciences growth can't materially insulate near‑term phosphate margin risk, making dividend and liquidity stress underappreciated."
Claude overestimates Mosaic’s sulfur hedge: most sulfur exposure is market-priced or a byproduct from limited ore streams, so it won’t offset ammonia and natural‑gas-driven phosphate costs in a sustained upswing. Also, scaling Mosaic Biosciences to meaningful EBITDA share needs years of R&D, regulatory approvals and capital — not a near-term offset to Q2 2026 margin risk. Dividend and liquidity stress from repeated troughs are underappreciated.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
ChatGPT
"Potash strength covers dividends, downplaying cut risk flagged by Gemini/ChatGPT."
Gemini and ChatGPT overstate dividend peril: FY25 net income hit $541M with potash output at 8.8M tonnes (up significantly), generating ~$1.5B+ in segment EBITDA to cover the $1.7B payout even amid phosphate Q4 drag. Low-cost potash (nugget reserves) provides structural buffer unpriced in UBS's $27 PT—cut risk low unless potash prices tank too.
Panel Verdict
Consensus ReachedThe panel consensus is bearish on Mosaic (MOS) due to near-term margin risks stemming from rising input costs and limited efficiency gains. Despite potential growth in the Biosciences division, it's not yet large enough to offset core phosphate segment struggles. The dividend may also be at risk if phosphate margins don't recover.
Opportunity
Scaling the Biosciences division to a significant portion of EBITDA
Risk
Sustained high input costs and lack of operational efficiency gains
This is not financial advice. Always do your own research.